Advertisement

Boon-Cher Goh, MD, on Cancer Drugs in Singapore: 3As (Availability, Accessibility, and Affordability)

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Advertisement

Advertisement

Jul

15

Today In Oncology

Gedatolisib Combinations Approved by FDA for HR-Positive/HER2-Negative Breast Cancer

FDA Grants Traditional Approval to Selpercatinib for Locally Advanced or Metastatic RET Fusion–Positive Solid Tumors

American Cancer Society Reports Latest Global Cancer Statistics

Setmelanotide in Patients With Acquired Hypothalamic Obesity From Brain Tumors

Previously Untreated Advanced NSCLC With High PD-L1 Expressionb PD-1/-L1 Inhibitor Monotherapy or Chemoimmunotherapy

Advertisement

© 2026 HSP News Service, L.L.C.